Literature DB >> 15579190

Acute management of pituitary apoplexy--surgery or conservative management?

John Ayuk1, Elizabeth J McGregor, Rosalind D Mitchell, Neil J L Gittoes.   

Abstract

BACKGROUND AND
OBJECTIVE: The rarity of pituitary apoplexy renders it a difficult subject for audit; hence there are no evidence-based standards of optimum care for such patients. The key controversy in management relates to the role of acute neurosurgical intervention. In recent years we have adopted a relatively conservative approach towards patients presenting with pituitary apoplexy. Against this background, we aimed to determine whether our less-interventional approach affected long-term clinical outcome in these patients. PATIENTS AND
DESIGN: A retrospective analysis was performed to evaluate clinical presentation, management and clinical outcomes in a cohort of patients who presented acutely with pituitary apoplexy during the period 1994-2004. Data from 33 patients (13 female) were included, with a mean age of 52 (range 27-79) years and mean follow-up duration of 3.7 (0.4-10.1) years.
RESULTS: The most common presenting symptoms were headache (97%), visual deficits (82%) and nausea/vomiting (78%). Fifteen patients (46%) underwent transsphenoidal surgery while 18 were managed conservatively. Indications for surgery were deteriorating visual deficit (n = 13), hemiparesis (n = 1) and altered conscious level (n = 1). Eight patients in the surgical group had ocular paresis that resolved in 63% following surgery, and seven had visual field defects with recovery in 57% postsurgery. Conservative management was reserved for patients with absent, or evidence of resolving, visual deficits at presentation. In this group, seven presented initially with ocular paresis and six with visual field defects but all made full recoveries. Of the patients managed neurosurgically, 87% required long-term glucocorticoid replacement and 60% required long-term thyroid hormone replacement. Conservatively managed patients required glucocorticoid replacement in 72% and thyroid hormone replacement in 72% of cases (P = NS between the two groups). Sex steroid replacement was required in 67% and 83% of patients managed neurosurgically and conservatively respectively (P = NS). At latest follow-up one patient in the conservatively managed group had required surgery and one in the surgically managed group had received pituitary radiotherapy, in both instances due to evidence of tumour regrowth on magnetic resonance imaging (MRI).
CONCLUSION: Our findings suggest that patients presenting with pituitary apoplexy in whom visual deficits are stable or improving may be managed expectantly as there is no identifiable deleterious effect on visual or endocrine outcome. One patient from each group experienced tumour regrowth that necessitated further treatment intervention, highlighting the importance of long-term follow-up in patients with pituitary apoplexy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15579190     DOI: 10.1111/j.1365-2265.2004.02162.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  42 in total

1.  Pituitary tumor apoplexy presenting as infective meningoencephalitis.

Authors:  Annachiara Cagnin; Andrea Marcante; Enrico Orvieto; Renzo Manara
Journal:  Neurol Sci       Date:  2011-06-01       Impact factor: 3.307

2.  Third, Fourth, and Sixth Cranial Nerve Palsies in Pituitary Apoplexy.

Authors:  Rabih Hage; Sheila R Eshraghi; Nelson M Oyesiku; Adriana G Ioachimescu; Nancy J Newman; Valérie Biousse; Beau B Bruce
Journal:  World Neurosurg       Date:  2016-07-17       Impact factor: 2.104

3.  Pituitary apoplexy during treatment of cystic macroprolactinomas with cabergoline.

Authors:  Giovanna Aparecida Balarini Lima; Evelyn de Oliveira Machado; Cintia Marques Dos Santos Silva; Paulo Niemeyer Filho; Mônica Roberto Gadelha
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

Review 4.  Pituitary apoplexy.

Authors:  Wenya Linda Bi; Ian F Dunn; Edward R Laws
Journal:  Endocrine       Date:  2014-07-26       Impact factor: 3.633

5.  Surgical treatment for severe visual compromised patients after pituitary apoplexy.

Authors:  Chi-Cheng Chuang; Chen-Nen Chang; Kuo-Chen Wei; Cheng-Chih Liao; Peng-Wei Hsu; Ying-Cheng Huang; Yao-Liang Chen; Li-Ju Lai; Ping-Ching Pai
Journal:  J Neurooncol       Date:  2006-04-28       Impact factor: 4.130

6.  A conservative management is preferable in milder forms of pituitary tumor apoplexy.

Authors:  C Leyer; F Castinetti; I Morange; M Gueydan; C Oliver; B Conte-Devolx; H Dufour; T Brue
Journal:  J Endocrinol Invest       Date:  2010-08-31       Impact factor: 4.256

7.  Pituitary tumor apoplexy in patients with Cushing's disease: endocrinologic and visual outcomes after transsphenoidal surgery.

Authors:  Osamah J Choudhry; Asad J Choudhry; Elkin A Nunez; Jean Anderson Eloy; William T Couldwell; Ivan S Ciric; James K Liu
Journal:  Pituitary       Date:  2012-09       Impact factor: 4.107

8.  Effect of transsphenoidal surgery on decreased visual acuity caused by pituitary apoplexy.

Authors:  Naoya Takeda; Katsuzo Fujita; Shigenori Katayama; Nobuyuki Akutu; Shigeto Hayashi; Eiji Kohmura
Journal:  Pituitary       Date:  2010-06       Impact factor: 4.107

9.  Perioperative visual loss in ocular and nonocular surgery.

Authors:  Kathleen T Berg; Andrew R Harrison; Michael S Lee
Journal:  Clin Ophthalmol       Date:  2010-06-24

Review 10.  Pituitary apoplexy: considerations on a single center experience and review of the literature.

Authors:  L Giammattei; G Mantovani; G Carrabba; S Ferrero; A Di Cristofori; E Verrua; C Guastella; L Pignataro; P Rampini; M Minichiello; M Locatelli
Journal:  J Endocrinol Invest       Date:  2016-01-05       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.